TRP_1170x120_3-8-19

Alcon

Gymnast Laurie Hernandez and Alcon team on new campaign

Gymnast Laurie Hernandez and Alcon team on new campaign

FORT WORTH — Alcon is teaming up with gold- and silver-medal winning gymnast Laurie Hernandez on a new campaign that encourages people to find inspiration to visualize and achieve their goals. The “Eye Can, Eye Will” campaign is based on Laurie’s belief that personal mantras and clear, comfortable vision with DAILIES TOTAL1 contact lenses have

Alcon shows millions with cataracts that color can come back to life

Alcon shows millions with cataracts that color can come back to life

FORT WORTH — Alcon has launched a new art-focused campaign in honor of Cataract Awareness Month, which illustrates the impact cataracts can have on seeing color and encourages those diagnosed with cataracts to understand the benefits of cataract surgery. The campaign is part of Alcon’s continued commitment to educate patients about cataracts and treatment options.

Alcon acquires PowerVision Inc.

Alcon acquires PowerVision Inc.

FORT WORTH — Alcon, the global leader in eye care and a division of Novartis, announced Monday that it has acquired PowerVision, Inc., a privately-held, US-based medical device development company focused on creating fluid-based intraocular lens implants. The acquisition furthers Alcon’s commitment to bring this innovative, accommodating lens to cataract patients throughout the world. Commercial availability

Alcon launches AIR OPIX Colors sweepstakes

Alcon launches AIR OPIX Colors sweepstakes

FORT WORTH — Alcon, a division of Novartis, is inviting consumers to change their eye color as part of the AIR OPTIX Colors contact lenses sweepstakes for a chance to go backstage at New York Fashion Week: The Shows in February 2019. To enter, people must wear or virtually try on one of 12 colors

Novartis seeks approval to spinoff Alcon eye care biz

Novartis seeks approval to spinoff Alcon eye care biz

BASEL — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder

Sandoz releases Pataday authorized generic

Sandoz releases Pataday authorized generic

PRINCETON, N.J. — Sandoz Inc. has launched olopatadine hydrochloride ophthalmic solution 0.2%, an antihistamine for itchy eyes, in the United States. Sandoz said the product is an authorized generic version of Pataday eye drops from Alcon. Both Sandoz and Alcon are subsidiaries of Novartis. A mast cell stabilizer, olopatadine hydrochloride ophthalmic solution 0.2% is indicated